• 1
    Harvima RJ, Schwartz LB. Mast cell derived mediators. In: ForemanJ, editor. Immunopharmacology of mast cells and basophils. London: Academic Press, 1993:115138.
  • 2
    Bradding P, Feather IH, Howarth PH, et al. Interleukin 4 is localized to and released by human mast cells. J Exp Med 1992;176:13811386.
  • 3
    Bressler RB, Lesko J, Jones ML, et al. Production of IL-5 and granulocyte-macrophage colony-stimulating factor by naive human mast cells activated by high-affinity IgE receptor ligation. J Allergy Clin Immunol 1997;99:508514.
  • 4
    Krüger-Krasagakes S, Möller A, Kolde G, Lippert U, Weber M, Henz BM. Production of interleukin-6 by human mast cells and basophilic cells. J Invest Dermatol 1996;106:7579.
  • 5
    Möller A, Lippert U, Lessmann D, et al. Human mast cells produce IL-8. J Immunol 1993;151:32613266.
  • 6
    Burd PR, Thompson WC, Max EE, Mills FC. Activated mast cells produce interleukin 13. J Exp Med 1995;181:13731380.
  • 7
    Ackermann L, Harvima IT, Pelkonen J, et al. Mast cells in psoriatic skin are strongly positive for interferon-gamma. Br J Dermatol 1999;140:624633.DOI: 10.1046/j.1365-2133.1999.02760.x
  • 8
    Irani AA, Bradford TR, Kepley CL, Schecter NM, Schwartz LB. Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J Histochem Cytochem 1989;37:15091515.
  • 9
    Harvima IT, Haapanen L, Ackermann L, Naukkarinen A, Harvima RJ, Horsmanheimo M. Decreased chymase activity is associated with increased levels of protease inhibitors in mast cells of psoriatic lesions. Acta Derm Venereol (Stockh) 1999;79:98104.
  • 10
    Kaminska R, Harvima IT, Naukkarinen A, Nilsson G, Horsmanheimo M. Alterations in mast cell proteinases and protease inhibitors in the progress of cutaneous herpes zoster infection. J Pathol 1996;180:434440.DOI: 10.1002/(sici)1096-9896(199612)180:4[amp]#60;434::aid-path682>;2-2
  • 11
    Schechter NM, Sprows JL, Schoenberger OL, Lazarus GS, Cooperman BS, Rubin H. Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors. J Biol Chem 1989;264:2130821315.
  • 12
    Harvima IT, Harvima RJ, Naukkarinen A, Horsmanheimo M. Skin tryptase: features and expression in human dermatological disorders. In: CaugheyGH, editor. Mast cell proteases in immunology and biology. New York: Marcel Dekker, 1995:2546.
  • 13
    Rubinstein I, Nadel JA, Graf PD, Caughey GH. Mast cell chymase potentiates histamine-induced wheal formation in the skin of ragweed-allergic dogs. J Clin Invest 1990;86:555559.
  • 14
    Travis J, Reilly C. The role of leukocyte cathepsin G and chymase in inflammation. In: OgawaH, LazarusGS, Hopsu-HavuVK, editors. The biological role of proteinases and their inhibitors in skin. Tokyo: University of Tokyo Press, 1985:121125.
  • 15
    Caughey GH, Leidig F, Viro NF, Nadel JA. Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J Pharmacol Exp Ther 1988;244:133137.
  • 16
    Schwartz LB, Atkins PC, Bradford TR, Fleekop P, Shalit M, Zweiman B. Release of tryptase together with histamine during the immediate cutaneous response to allergen. J Allergy Clin Immunol 1987;80:850855.
  • 17
    He S, Gaça MDA, Walls AF. A role for tryptase in the activation of human mast cells: modulation of histamine release by tryptase and inhibitors of tryptase. J Pharmacol Exp Ther 1998;286:289297.
  • 18
    Worm M, Henz BM. Molecular regulation of human IgE synthesis. J Mol Med 1997;75:440447.
  • 19
    Xia HZ, Du Z, Craig S, et al. Effect of recombinant human IL-4 on tryptase, chymase, and Fce receptor type I expression in recombinant human stem cell factor-dependent fetal liver-derived human mast cells. J Immunol 1997;159:29112921.
  • 20
    Yamaguchi M, Sayama K, Yano K, et al. IgE enhances Fce receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fce receptor I expression and mediator release. J Immunol 1999;162:54555465.
  • 21
    Bischoff SC, Sellge G, Lorentz A, Sebald W, Raab R, Manns MP. IL-4 enhances proliferation and mediator release in mature human mast cells. Proc Natl Acad Sci U S A 1999;96:80808085.DOI: 10.1073/pnas.96.14.8080
  • 22
    Okayama Y, Ono Y, Nakazawa T, Church MK, Mori M. Human skin mast cells produce TNF-alpha by substance P. Int Arch Allergy Immunol 1998;117 Suppl 1:4851.
  • 23
    Horsmanheimo L, Harvima IT, Järvikallio A, Harvima RJ, Naukkarinen A, Horsmanheimo M. Mast cells are one major source of interleukin-4 in atopic dermatitis. Br J Dermatol 1994;131:348353.
  • 24
    Järvikallio A, Naukkarinen A, Harvima IT, Aalto M-L, Horsmanheimo M. Quantitative analysis of tryptase-, and chymase-containing mast cells in atopic dermatitis and nummular eczema. Br J Dermatol 1997;136:871877.
  • 25
    Tunon de Lara JM, Okayama Y, McEuen AR, Heusser CH, Church MK, Walls AF. Release and inactivation of interleukin-4 by mast cells. Ann N Y Acad Sci 1994;725:5058.
  • 26
    He S, Gaça MDA, McEuen AR, Walls AF. Inhibitors of chymase as mast cell-stabilizing agents: contribution of chymase in the activation of human mast cells. J Pharmacol Exp Ther 1999;291:517523.
  • 27
    Horsmanheimo L, Harvima IT, Harvima RJ, Ylönen J, Naukkarinen A, Horsmanheimo M. Histamine release in skin monitored with the microdialysis technique does not correlate with the weal size induced by cow allergen. Br J Dermatol 1996;134:94100.
  • 28
    Poulsen LK, Liisberg C, Bindslev-Jensen C, Malling H-J. Precise area determination of skin-prick tests: validation of a scanning device and software for a personal computer. Clin Exp Allergy 1993;23:6168.
  • 29
    Saarinen JV, Harvima RJ, Naukkarinen A, Horsmanheimo M, Harvima IT. Release of histamine and leukotriene C4 in immediate allergic wheal reaction as measured with the microdialysis technique. Arch Dermatol Res 2000 ;292:333–340.
  • 30
    He S, Peng Q, Walls AF. Potent induction of a neutrophil and eosinophil-rich infiltrate in vivo by human mast cell tryptase: selective enhancement of eosinophil recruitment by histamine. J Immunol 1997;159:62166225.
  • 31
    Ricci M, Matucci A, Rossi O. Source of IL-4 able to induce the development of TH2-like cells. Clin Exp Allergy 1997;27:488500.
  • 32
    Wang M, Saxon A, Diaz-Sanchez D. Early IL-4 production driving Th2 differentiation in a human in vivo allergic model is mast cell derived. Clin Immunol 1999;90:4754.DOI: 10.1006/clim.1998.4628
  • 33
    Deschoolmeester ML, Eastmond NC, Dearman RJ, Kimber I, Basketter DA, Coleman JW. Reciprocal effects of interleukin-4 and interferon-γ on immunoglobulin E-mediated mast cell degranulation: a role for nitric oxide but not peroxynitrite or cyclic guanosine monophosphate. Immunology 1999;96:138144.DOI: 10.1046/j.1365-2567.1999.00662.x
  • 34
    Atkins MB, Vachino G, Tilg HJ, et al. Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancies. J Clin Oncol 1992;10:18021809.
  • 35
    Gilleece MH, Scarffe JH, Ghosh A, et al. Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections – a phase I dose toxicity trial. Br J Cancer 1992;66:204210.